欧洲斯托克600指数收盘下跌0.5%。金融服务、媒体和旅游股跌幅居前，与贸易相关的汽车和工业板块 承压。个人护理和公用事业板块表现强于大盘。 欧洲议会主要政治团体周一表示，将暂停推进批准美欧贸易协议的立法工作。此前，美国最高法院推翻 了特朗普的全球关税措施，特朗普随即宣布征收新的全球关税，并誓言动用其他权力维持其标志性的关 税政策。 最高法院裁决后，"目前看来可选措施似乎有限，力度也没那么大"，这对消费股等板块来说应属利好， KBC Securities全球股票主管Andrea Gabellone表示。尽管如此，他表示，"问题在于，其他市场参与者是 否愿意承受接下来势将充满'波动'的关税消息。" 来源：环球市场播报 投资者原本就在艰难应对有关估值偏高以及人工智能带来的颠覆性影响的担忧，关税相关消息再添复杂 因素。同时，市场也在关注伊朗局势的发展。美伊双方将于周四进行新一轮会谈，寻求通过外交途径化 解围绕德黑兰核计划的僵局。 欧洲股市下跌，特朗普最新的关税行动为全球贸易前景带来新的不确定性。诺和诺德股价重挫，此前其 新一代减重注射药物在一项试验中表现不及礼来的一款重磅竞品。 本周市场面临的重大事件包括特朗普周二 ...

LOS ANGELES--(BUSINESS WIRE)--Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO. ...

Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‌gains brought by its blockbuster weight-loss drug Wegovy, ‌after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's ​rival. Novo, which in 2024 was worth more than $650 billion, has since shed around $475 billion, with the shares back at levels last seen before Wegovy transformed it into Europe's most ‌valuable drugmaker. Novo's shares ⁠fell to their lowest level s ...

Eli Lilly Gains as Novo Nordisk Trial SetbackNovo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did n ...

Novo Nordisk AS (NYSE:NVO) , once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what analysts are calling a “worst-case scenario.” NVO stock is tumbling. See the chart and price action here. Shares of Novo Nordisk stock plunged over 16% in morning trading, hitting a new 52-week low following disappointing results from the REDEFINE 4 Phase 3 clinical trial. This latest blow brings the stock’s one month decline to 36%.The Data Gap: CagriSema vs. TirzepatideThe 84-week trial i ...

This means it could keep moving lower, which is why it's our Stock of the Day.Like any market, supply and demand drive the stock market. If a stock trends lower, there’s more supply, or shares for sale, than there are to be bought.This results in a downtrend. It forces traders and investors to undercut each other's prices.But when a stock reaches a support level, the buyers flood the market. There are enough buy orders to take in or absorb all of the sell orders, so the price stops going down.As you can see ...

-- Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why [Stocks Lose Ground Amid Tariff Uncertainty][Trump's 'Plan B' on Tariffs: More Tariffs][Economy Grew Far Less Than Expected in Q4][Inflation Likely to Keep Fed from Cutting Rates Soon]- Top StoriesWith Monday's drop, Novo Nordisk shares have lost more than half their value in the last 12 months.Kristian Tuxen Ladegaard Berg / NurPhoto / Getty ImagesClose### Key Takeaways- Novo Nordisk's CagriSema, its next-generation weig ...

Novo Nordisk (NYSE: NVO) is taking it on the chin this morning, after revealing the latest clinical trial results for weight loss using its CagriSema drug (a 50-50 mix of amylin analog cagrilintide and Novo's glucagon-like peptide-1 (GLP-1) receptor agonist). After an 84-week trial, Novo reported that its patients achieved 23% weight loss with the drug. That sounds like pretty good news, but investors don't seem to like the number -- and as of 10:10 a.m. ET, Novo Nordisk stock is down 14.8%. Where to inve ...

Group 1 - Novo Nordisk A/S stock has decreased by 14.9% to $40.38 after a trial indicated that its weight loss drug CagriSema was less effective than Eli Lilly's tirzepatide [1] - The stock reached a four-year low of $39.97 and is on track for a fifth consecutive loss, marking its largest single-day percentage drop since July [1] - Over the past year, Novo Nordisk shares have declined by more than 54% [1] Group 2 - Options traders are showing a bullish sentiment, as indicated by a 50-day call/put volume ratio of 4.26, which is higher than 92% of readings from the past year [2] - Today's options activity includes 72,000 calls and 57,000 puts, which is five times the typical volume for this time [3] - The most popular options contracts are the weekly 3/6 40-strike put and May 35 call, with new positions being opened [3] Group 3 - Novo Nordisk has outperformed traders' volatility expectations over the past year, reflected in a Schaeffer's Volatility Scorecard (SVS) of 80 out of 100 [4] - The Schaeffer's Volatility Index (SVI) for Novo Nordisk is in the 23rd percentile of annual readings, suggesting that options are currently affordable [4]

美国贸易政策前景不明令市场情绪承压，美股三大指数集体低开，纳指跌0.03%，道指跌0.31%，标普 500指数跌0.03%。科技股普跌，特斯拉、甲骨文跌超1%。诺和诺德大跌15%，该公司新一代减肥药 CagriSema的试验效果不及礼来的Zepbound。 ...